Home → E-shop → Nucleotides → Islatravir monophosphate – CAS 950913-58-3

Islatravir monophosphate – CAS 950913-58-3

Islatravir monophosphate – CAS 950913-58-3 is synthesised by Sigut Labs (Prague, Czech Republic).

Purity (LC-MS)

97%+

Package contents

Islatravir monophosphate triethylammonium salt

This compound is for research use only. We do not sell to patients.

Amount

1 mg	€ 1150	Stock
5 mg	€ 2500	Stock
Do you want custom amount?			Custom amount

Amount

1 mg

€ 1150

Stock

5 mg

€ 2500

Stock

Do you want custom amount?

Custom amount

Characterisation

CAS: 950913-58-3

IUPAC name: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate

Other names: EFdA-MP, MK-8591-MP

Molecular weight: 373.24 g/mol

Molecular formula: C₁₂H₁₃FN₅O₆P

InChI: InChI=1S/C12H13FN5O6P/c1-2-12(4-23-25(20,21)22)6(19)3-7(24-12)18-5-15-8-9(14)16-11(13)17-10(8)18/h1,5-7,19H,3-4H2,(H2,14,16,17)(H2,20,21,22)/t6-,7+,12+/m0/s1

Description

Islatravir monophosphate is synthesised by Sigut Labs (Prague, Czech Republic) and it is a metabolite of Islatravir. Islatravir (EFdA, or MK-8591) is an investigational drug for the treatment of HIV infection developed by company Merck. It is classified as a nucleoside reverse transcriptase translocation inhibitor (NRTTI). Islatravir has activity against HIV in animal models and is being studied clinically for HIV treatment and prophylaxis. Islatravir is a nucleoside analogue reverse transcriptase translocation inhibitor that, unlike other such inhibitors, inhibits HIV through multiple mechanisms, providing rapid suppression of the virus, when tested in macaques and mice. Islatravir inhibits HIV reverse transcriptase but has a different mechanism of action with respect to all other approved NRTIs because of its unique structural features: a 3’-hydroxyl group makes this nucleotide a translocation inhibitor rather than a chain terminator. Introducing a 4’-ethynyl group enhances the selectivity towards the HIV reverse transcriptase. Similarly to other nucleoside antiviral drugs, Islatravir is first transformed to islatravir-5’-triphosphate (ISL-TP), which is the biologically active form of Islatravir. When ITP is incorporated into forming DNA strand by the reverse transcriptase, it acts as a chain terminator by preventing the translocation.

Based on its unique properties, Merck is currently developing a sub-dermal implant for the long-term release of Islatravir. This implant is now under clinical evaluation and is likely to cause a revolution in HIV treatment. You can find more information about Islatravir in our article.

Chemicals are distributed worldwide

Buy Islatravir monophosphate now, and get your order in 48 hours

Shipping through DHL in 48 hours
Sensitive compounds are shipped on dry ice
All compounds are safely and rigorously packed

Payment

Payment terms 30 days net
We are sending the invoice the same day as the shipment
We are able to modify the invoice for the academic institution, so the order can be paid from grants

References

Matthews, R. P., Ankrom, W., Friedman, E., Jackson Rudd, D., Liu, Y., Mogg, R., … & Iwamoto, M. (2021). Safety, tolerability, and pharmacokinetics of single‐and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV. Clinical and Translational Science, 14(5), 1935-1944.
Wonganan, P., Limpanasithikul, W., Jianmongkol, S., Kerr, S. J., & Ruxrungtham, K. (2020). Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection. Expert Opinion on Drug Metabolism & Toxicology, 16(7), 551-564.